MEDICAMEN Biotech Limited

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2026-27 **Date: 17.08.2026**

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

BSE Code-531146

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

NSE Code: MEDICAMEQ

Sub. : Copy of Publication for Un-audited Financial Results for the quarter ended on June 30, 2026

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed newspaper cutting with regard to the publication of extract of Un-audited Financial Results of the Company for the quarter ended on June 30, 2026 approved by the Board of Directors at their Meeting held on 14.08.2026.

The copy of the results published in the Financial Express and Jansatta dated 15.08.2026 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

PARUL CHOUDHARY
Digitally signed by PARUL CHOUDHARY
Date: 2026.08.17 15:30:31 +05'30'

Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, 110019 (India)
CIN: L74899DL1993PLC056594 Contact No.: 011-47589500
Website: www.medicamen.com Email: info@medicamen.com

Statement of Un-audited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on August 14, 2026, approved the Un-audited financial results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:

For and on behalf of Board of Directors
Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Director
DIN: 00317960

Place: New Delhi
Date: 14.08.2026

Bilcare Research

Bilcare Limited

Regd. Office : 1028, Shiroli, Pune 410505.**Tel :** +91 2135 647300
Fax : +91 2135 224068 **Email:** cs@bilcare.com
Website: www.bilcare-group.com **CIN :** L28939PN1987PLC043953

Extract of Consolidated Financial Results (Unaudited) for the quarter ended June 30, 2026

(₹ in Crores, except per share data)

Sr. No.	Particulars	Quarter Ended		Year Ended
		30 June 2026	30 June 2025	31 March 2026
		(Unaudited)	(Unaudited)	(Audited)
1.	Total Income from Operations	227.61	192.44	763.54
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	16.58	(6.04)	(17.66)
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	14.84	(6.04)	(21.46)
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items)	14.97	(2.84)	(17.29)
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income]	13.86	(2.66)	(13.77)
6.	Equity Share Capital	23.55	23.55	23.55
7.	Reserves i.e. Other equity*	-	-	173.18
8	Earnings Per Share (after exceptional items) (of ₹ 10/- each)			
	a. Basic	5.39	1.34	0.73
	b. Diluted	5.39	1.34	0.73

** represents the audited financial figures for March 2026.*

Key Standalone Financial Information (₹ in Crores)

Sr. No.	Particulars	Quarter Ended		Year Ended
		30 June 2026	30 June 2025	31 March 2026
		(Unaudited)	(Unaudited)	(Audited)
1.	Total Income from Operations	6.30	8.79	26.38
2.	Profit / (Loss) Before Tax	0.91	4.49	1.56
3.	Profit / (Loss) After Tax	1.04	3.59	0.99

Notes:

1 The above is an extract of the detailed format of the quarter ended unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarter ended unaudited financial results are available on the Stock Exchange website - www.bseindia.com and on the Company's website - www.bilcare-group.com

2 Previous periods' figures have been re-grouped / re-classified wherever necessary.

Place : Pune
Date : August 13, 2026

For **Bilcare Limited**
Shreyans M. Bhandari
Managing Director

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

Shivalik Rasayan Limited

Corporate Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-19
CIN: L24237UR1979PLC005041Tel: +91 11 47589500 (30 Lines), 26221811/26418182
E-Mail : info@shivalikrasayan.com Website: www.shivalikrasayan.com

Statement of Un-audited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on August 14, 2026, approved the Un-audited financial results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026.

The financial results along with Limited Review Report have been posted on the website of the Company at www.shivalikrasayan.com and can be accessed by scanning the QR code given below

For and on behalf of Board of Directors of Shivalik Rasayan Limited
Sd/-
Rahul Bishnoi
Director
DIN: 00317960

Place: New Delhi
Date: 14.08.2026

MAX ESTATES LIMITED

(**CIN:** L70200DL2016PLC438718)
Registered office: Max House 1, Dr. Jha Marg, Okhla Phase 3, Opposite Okhla Railway Station, Okhla Industrial Estate, New Delhi-110020, India **Corporate Office:** Max Towers, L-20, C-001/A/1, Sector - 16B, Noida ,Gautam Buddha Nagar- 201301, Uttar Pradesh, India, **Tel:** +91 120 474 3222
Email: secretarial@maxestates.in, **Website:** www.maxestates.in

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

The Board of Directors of the Company, at the meeting held on August 14, 2026, approved the unaudited financial results of the Company for the quarter ended June 30, 2026.

The results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com, and on the company's website (URL: https://maxestates.in/wp-content/uploads/2026/08/Standalone-and-Consolidated-Results-for-the-Quarter-ended-June-30-2026.pdf). The same can be accessed by scanning the Quick Response Code provided below.

By order of the Board
For **Max Estates Limited**

Noida
August 14, 2026

Sahli Vachani
Vice-Chairman & Managing Director

***Note** - The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Lisiting Obligations & Disclosure Requirements) Regulations, 2015*

SANSTAR LIMITED

CIN: L15400GJ1982PLC072555
Regd. Office: "Sanstar House" Opp. Suvidha Shopping Center, Nr. Parimal Under Bridge, Paldi, Ahmedabad 380007;
Tel: +91 79 26651819-20-21 **Fax:** +91 79 26651822 **Email:** md@sanstar.in **Website:** www.sanstar.in

UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026.

The Board of Directors of the Company, at its meeting held on August 13, 2026, inter alia approved the Unaudited Standalone and Consolidated financial results for the quarter ended June 30, 2026.

The Unaudited Standalone and Consolidated financial result of the Company along with the Limited Review Report, are available on the Stock Exchange websites at www.bseindia.com and www.nseindia.com and are also posted on the Company's website at https://www.sanstar.in/investors-relations/financial-information/Quarterly Financial Result Q1-FY 2026-27/ which can be accessed by scanning the Quick Response (QR) Code.

For, SANSTAR LIMITED
Gouthamchand Sohanlal Chowdhary
Chairman & Managing Director
(DIN:00196397)

Place: Ahmedabad
Date: August 13, 2026

Note: The above intimation is in accordance with Regulation 33 read with regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirement) Regulation, 2015

CONCEPT

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, 110019 (India)
CIN: L74899DL1993PLC056594 Contact No.: 011-47589500
Website: www.medicamen.com Email: info@medicamen.com

Statement of Un-audited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on August 14, 2026, approved the Un-audited financial results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026.

The financial results along with Limited Review Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:

For and on behalf of Board of Directors
Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Director
DIN: 00317960

Place: New Delhi
Date: 14.08.2026

Reliance Infrastructure

Reliance Infrastructure Limited

CIN: L75100MH1929PLC001530
Registered Office: Reliance Centre, Ground Floor, 19, Walchand Hirachand Marg, Ballard Estate, Mumbai - 400 001.
Tel: +91 22 43031000 Website: www.rinfra.com, Email: rinfra.investor@reliancegroupindia.com

Statement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

The Board of Directors of the Company, at the meeting held on August 14, 2026, approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 ("Financial Results").

The Financial Results along with the Limited Review Reports, have been posted on the Company's website at www.rinfra.com and on the website of the Stock Exchanges www.bseindia.com and www.nseindia.com and can also be accessed by scanning this QR code.

For and on behalf of the Board of Directors of
Reliance Infrastructure Limited

Sd/-
Vijesh Babu Thota
Executive Director and CEO

Date: August 14, 2026
Place: Mumbai

JTPM METAL TRADERS LIMITED

Registered Office: JSW Centre, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. **CIN:** U46620MH2017PLC405988

EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in Lakhs)

Sr. No.	Particulars	Standalone			
		Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Refer Note 4	Unaudited	Audited
1	Total Income from Operations	-	7,978.25	167.35	13,304.42
2	Net Profit / (Loss) for the period/ year (before Tax, Exceptional and/or Extraordinary items)	(5,220.63)	(3,899.21)	(3,224.68)	(7,144.24)
3	Net Profit / (Loss) for the period/ year before tax (after Exceptional and/or Extraordinary items)	(5,220.63)	(3,899.21)	(3,224.68)	(7,144.24)
4	Net Profit / (Loss) for the period/ year after tax (after Exceptional and/or Extraordinary items)	(5,198.02)	(5,011.73)	(3,240.79)	(6,683.10)
5	Total Comprehensive Income/ (Loss) for the period / year (after tax) and other comprehensive income (after tax)	97,949.06	(84,297.77)	(36,375.95)	(27,608.53)
6	Paid up Equity Share Capital	131,703.00	131,703.00	131,703.00	131,703.00
7	Reserves (excluding Revaluation Reserves)	603,378.84	505,429.79	496,664.91	505,429.79
8	Securities Premium Account	28,358.78	28,358.78	28,358.78	28,358.78
9	Net worth	735,081.84	637,132.79	628,367.91	637,132.79
10	Paid up Debt Capital / Outstanding Debt	865,051.97	864,557.31	283,248.69	864,557.31
11	Outstanding Redeemable Preference Shares	-	-	-	-
12	Debt Equity Ratio	1.18	1.36	0.45	1.36
13	Earnings per share (of ₹10 each)				
	Basic (₹)	(0.04)	(0.04)	(0.25)	(0.51)
	Diluted (₹)	(0.04)	(0.04)	(0.25)	(0.51)
14	Capital Redemption Reserve	-	-	-	-
15	Debenture Redemption Reserve	NA	NA	NA	NA
16	Debt Service Coverage Ratio	(0.001)	(0.001)	0.002	0.072
17	Interest Service Coverage Ratio	(0.001)	(0.001)	0.050	0.072

Notes:

1 The above is extract of the detailed format of the Standalone unaudited Financial Results for the quarter ended 30 June 2026, as filed with BSE Limited under Regulation 52 of the SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015. The detailed financial information for the quarter and half year is available on the Company's website of BSE Limited.

2 The above results are in accordance with the companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of Companies Act 2013 read with relevant rules issued thereunder and other Accounting Principles generally accepted in India.

3 For the other line items referred in Regulations 52(4) SEBI (Listing and Other Disclosure Requirements) Regulation 2015, pertinent disclosures have been made to the stock exchanges website of the Stock Exchange at www.bseindia.com.

4 The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respective of full financial year and the published year to date figures upto the third quarter for the relevant financial year which was subjected to limited review by statutory auditor.

For JTPM Metal Traders Limited
Sd/-
Rajesh Patil
Whole Time Director
DIN: 09531534

Place: Mumbai
Date: August 13, 2026

NIYOGIN FINTECH LIMITED

Registered Office: MIG 944, Ground Floor, TNHB Colony, 1st Main Road, Velachery, Chennai, Tamil Nadu- 600042
Corporate Office: Neelkanth Corporate IT Park, 311/312, Kirol Road,Vidyavihar (West), Mumbai - 400086
CIN: L65910TN1988PLC131102
Email ID : investorrelations@niyogin.in **Website :** www.niyogin.com

Extract of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

Rupees in Lacs

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended			Year ended	Quarter ended			Year ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited)	30 June 2025 (Unaudited)	31 March 2026 (Audited)	30 June 2026 (Unaudited)	31 March 2026 (Audited)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
1	Total Income from Operations	2,981.29	2,994.50	2,640.35	11,792.69	6,675.61	7,740.71	8,614.06	32,081.46
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	81.56	154.48	59.83	511.22	(615.67)	141.92	(75.91)	418.40
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	81.56	154.48	59.83	511.22	(615.67)	141.92	(75.91)	340.94
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	81.56	154.48	59.83	511.22	(500.72)	111.32	(185.26)	37.03
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	81.56	154.48	59.83	511.22	(500.72)	133.75	(185.26)	84.31
6	Equity Share Capital (Face value of Rs. 10/- each)	11,124.74	11,124.74	11,112.74	11,124.74	11,124.74	11,124.74	11,112.74	11,124.74
7	Other Equity	25,029.65	24,927.69	24,319.94	24,927.69	21,069.82	21,389.61	21,111.03	21,389.61
8	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	-	-	-	-	-	-
9	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -								
	Basic :	0.07	0.14	0.05	0.46	(0.24)	0.06	(0.14)	(0.05)
	Diluted :	0.07	0.14	0.05	0.46	(0.24)	0.06	(0.14)	(0.05)
10	Networth	36,154.39	36,052.43	35,432.68	36,052.43	32,661.76	33,210.10	32,796.83	33,210.10
11	Debt Service Coverage Ratio (DSCR)	NA	NA	NA	NA	NA	NA	NA	NA
12	Interest Service Coverage Ratio (ISCR)	NA	NA	NA	NA	NA	NA	NA	NA
13	Debt Equity Ratio	0.25	0.35	0.21	0.35	0.43	0.68	0.34	0.68
14	Capital Redemption Reserve	NA	NA	NA	NA	NA	NA	NA	NA

Notes: a. The above is an extract of the detailed format of financial results for the quarter ended June 30, 2026, prepared pursuant to Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') read with SEBI circular dated July 05, 2016. The full format of the financial results (standalone and consolidated) are filed with the Stock Exchanges and are available on the websites of BSE Limited at www.bseindia.com and Niyogin Fintech Limited at www.niyogin.com. The same can also be accessed by scanning the QR code provided.
b. For other line items referred in regulation 52(4) of the SEBI Listing Regulations, pertinent disclosures have been made to the Stock Exchange - BSE Limited and can be accessed on the websites of BSE Limited at www.bseindia.com and Niyogin Fintech Limited at www.niyogin.com.

For Niyogin Fintech Limited
Sd/-
Tashwinder Singh
MD & CEO
DIN: 06572282

Date: August 13, 2026
Place: Mumbai